
Haley B. Naik, M.D., on the hidradenitis suppurativa guideline recommendations most likely to change clinical practice practice
Naik says a strong recommendation for infliximab and a call for routine pain assessment are the HS guideline changes most likely to change clinical practice.
The first joint guidelines of care for
Naik noted the strong recommendation for the use of
Naik said the odds of an industry-sponsored trial of infliximab in HS are "slim to none" because the drug is off patent and
The second recommendation that Naik highlighted as practice changing is a good practice statement calling on clinicians to routinely ask patients with HS about pain, using tools such as a visual analog scale or a zero-to-10 rating at each visit. The guidelines report that 61% of patients with HS have moderate to severe pain, and Naik said pain limits patients' ability to function, attend school and work.
Naik said the recommendation reflects input from patients and advocacy groups as well as gaps in physician training. Little is known about what causes HS pain or how best to assess and treat it, a research gap that Naik said is ripe for investigation.
Related to this article








